Delivery Order SPE2DB24D1006-SPE2DB25FCEZZ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for TIVICAY 50 mg tablets (30-count units) valued at $5,448.89 under a firm fixed-price contract type. The award, issued on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $4,002.93 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tivicay 50 mg tablets (30-count packages). The contract is a firm fixed-price delivery order with a completion date of September 10, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order represents a task order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 30 tablets of Tivicay 50 mg with a ceiling value of $11,725.91. Issued on June 6, 2025, this firm fixed-price delivery order is set to be completed by June 9, 2025. The contract will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. This award represents a competitive, non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $20,950.35 to AmerisourceBergen Drug Corp for 30-count bottles of Tivicay 50 mg tablets. This competitive award was issued on September 4, 2025, with an ultimate completion date of September 5, 2025, and represents a firm fixed-price delivery order with no set-aside designation. The pharmaceutical will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,277.11 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Tivicay 50 mg tablets (30-count units). This is a firm fixed price delivery order with no set-aside designation, representing a competitive award under the company's existing contract vehicle. Performance will occur at the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. This...
- The Defense Logistics Agency awarded a delivery order valued at $6,671.60 to AmerisourceBergen Drug Corp for 30 tablets of Tivicay 50 mg on July 23, 2025, with completion expected by July 24, 2025. This firm fixed price delivery order, with no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Tivicay is an antiretroviral medication used in HIV treatment, reflecting the Defense Logistics Agency's ongoing pharmaceutical...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tivicay 50 mg tablets (30-count) valued at $2,871.67 on July 25, 2025, with completion expected by July 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $6,928.84 to AmerisourceBergen Drug Corp for Tivicay 50 mg tablets (30-count packages) on August 27, 2025, with completion scheduled for August 28, 2025. This competitively awarded, firm fixed-price delivery order represents a single-item pharmaceutical procurement with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this requirement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Tivicay 50 mg tablets in quantities of 30, with a contract ceiling value of $23,342.52. This firm fixed-price delivery order, which is expected to be completed by August 26, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Tivicay 50 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $4,178.97. This delivery order represents a non-set-aside award issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle valued through December 2026. The place of performance is...
- SPE2DB24D1006Indefinite Delivery Contract
- SPE2DB24D1006-SPE2DB25FCEZZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Tivicay 50 mg tablets (30-count units) under a firm fixed-price contract valued at $10,353.99. The award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order falls under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement extending through December 2026 that enables comprehensive pharmaceutical supply support for military healthcare systems globally. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Tivicay is an antiretroviral medication used in HIV treatment, consistent with the company's extensive portfolio of pharmaceutical products spanning specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. The firm fixed-price structure and rapid completion timeline reflect standard delivery order practices under the DLA's global pharmaceutical prime vendor framework, demonstrating the company's established capability to fulfill federal medical supply requirements through competitive procurement mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.4k | 8/14/25 |